… therapy in ARDS and sepsis is discussed. The potential for MSC therapy in COVID-19 ARDS
is … of MSC therapy in COVID-19. Strategies to optimize the therapeutic potential of MSCs in …

… respiratory failure, heart disease and impaired immune status are at enhanced risk of more
severe COVID-19, including ARDS, multiorgan failure, and death [39,44]. This severe form of …

… COVID-19 In the past 50 years, the potential benefit of corticosteroids in treating sepsis or
acute respiratory distress syndrome (ARDS) … were efficacious for ARDS of various origin. This …

… occur in severe COVID-19, influenza-associated ALI/ARDS and sepsis and also differentiate
… COVID-19 and influenza virus or bacterial infections that do not lead to ALI/ARDS or sepsis. …

… To analyze shared genetic interrelations and potential therapeutic targets among COVID-19,
ARDS and sepsis, we obtained both microarray and RNA-seq datasets from the Gene …

… ARDS and sepsis (9). If the inflammatory response in severe COVID-19 is no different than
that in ARDS or sepsis, testing of immune modulators in unselected COVID-19 patients may …

… COVID-19 patients (78%) met the Sepsis 3.0 criteria for sepsis/septic shock with acute respiratory
distress syndrome … Conversely, COVID-19 ARDS features a robust alveolar thrombosis …

… In our study, 158 TAGs and 29 DAGs had higher levels in COVID-19 ARDS compared to
bacterial sepsis-induced ARDS while 102 TAGs and 3 DAGs had lower levels. …

… with sepsis and 177 patients with sepsis and COVID-19 were enrolled in this study. These
177 sepsis patients with COVID-19 … Mortality in COVID-19 caused ARDS patients seems to be …

… as biomarkers for predicting COVID-19 and sepsis-induced ARDS, we employed a murine
model of sepsis-induced ARDS as a proxy for both COVID-19 and sepsis-related lung injuries…